"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO. The rationale for this study is ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

Tang discusses the limitations in available data, but nonetheless high potential, of SBRT in kidney cancer. As Tang noted in his ASTRO 2024 presentation topic, SBRT has been linked to significantly ...

“We need to close that gap, and just as a general rule, screen our prostate cancer patients more closely for depression, especially those with androgen deprivation therapy,” says Mihir S. Shah, MD. In ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

Aquablation offers a versatile treatment for BPH, accommodating various prostate sizes and shapes, with a relatively flat learning curve for urologists. Proper patient selection is crucial for ...

The study evaluates Focal One robotic HIFU for BPH, focusing on safety and efficacy in a phase 1/2 trial. Phase 1 determines optimal treatment parameters, while phase 2 expands enrollment to assess ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

Androgen deprivation therapy significantly increases depression risk in prostate cancer patients, with a 60% higher incidence rate. White patients on androgen deprivation therapy are more likely to be ...

ART post-RC in MIBC patients shows no significant increase in acute or late toxicity, with mild bowel toxicity being more frequent. Historical concerns about bowel exposure have limited ART use, but ...

Elevated baseline CTC count in mHSPC patients is linked to poor PSA response, rapid progression, and decreased overall survival. The study analyzed 1313 samples, finding that 11.9% had 5 or more CTCs ...

The FDA approved an IDE trial comparing Aquablation therapy with radical prostatectomy for localized prostate cancer. Aquablation therapy has Breakthrough Device Designation and is approved for LUTS ...